1000X More Efficient Neural Networks: Building an Artificial Brain With 86 Billion Physical (but Not Biological) Neurons
What if in our attempt to build artificial intelligence we don’t simulate neurons in code and mimic neural networks in Python, but instead build actual physical neurons connected by physical synapses in ways very similar to our own biological brains? That’s precisely what UF startup Rain Neuromorphics, is trying to do: build a non-biological yet very human-style artificial brain.
Exactech Announces New Patent, Strengthening Company’s Position in Joint Replacement Soft Tissue Management
UF startup Exactech, announces new patent or the Newton™ Knee, a dynamic platform of cutting-edge technology used with forward-thinking implants that are designed to provide optimal balance in a reproducible way.
Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on Its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
Oragenics, Inc., announced the initiation of a Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile and immunogenicity of its NT-CoV2-1 vaccine
Dialectic Therapeutics Announces DT2216 Has Received Orphan Drug Designation From the FDA for the Treatment of T-Cell Lymphoma
UF startup Dialectic Therapeutics, Inc. (Dialectic®), announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DT2216 for the treatment of T-cell lymphoma.
World Glaucoma Week: A Retina Specialist’s Guide to Recent Innovations in Glaucoma
Ophthalmologists and researchers have made great strides in the management of glaucoma. From implants and robotics to proper administration of eye drops, glaucoma is treated more effectively than ever. This article highlights some of the latest discoveries in glaucoma, including work by UF startup and Sid Martin Biotech company TearClear.
Lacerta Therapeutics Expands Executive Leadership Team
UF startup Lacerta Therapeutics, a preclinical-stage gene therapy company, announces an expansion in the executive leadership team: illustrating Lacerta’s commitment to developing a constellation of gene-based therapies.
RTI Surgical: Plant Director’s Passion and Engagement Inspires Team
A passion to find a position with a company that directly impacts people's lives led Catisha Turner to join UF startup RTI Surgical, after serving in the United States Navy for six years.
Cannabix Technologies Presents FAIMS Marijuana Breathalyzer Technology at the Texas Impaired Driving Forum
UF startup Cannabix Technologies Inc., presented key innovations for first-of-its-kind marijuana breath detection technology. This comes at a time when legislators are grappling with the ever-increasing problem of drugged driving.
Capri EGM Build-to-Suit Program Acquires Life Science Real Estate Asset for Company Manufacturing Antibodies for Department of Defense and mRNA for COVID-19 Vaccine
UF startup Ology Bioservices, a wholly owned subsidiary of Resilience, and the operator of the Lab & Research facility, has recently been awarded contract valued as much as $250 million by the Department of Defense for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT).
GrowFL Announces Lacerta Therapeutics as an Honoree: 11th Annual Florida Companies to Watch
Lacerta Therapeutics is pleased to be among the top 50 second-stage companies in Florida selected as an 11th Annual GrowFL Florida Companies to Watch honoree, a statewide competition that identifies companies expected to see significant growth over the next several years.
